Fund size | GBP 17 m |
Total expense ratio | 0.49% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in GBP) | 15.12% |
Inception/ Listing Date | 17 January 2018 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | Legal & General (LGIM) |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
Investment Advisor | Legal & General Investment Management Limited |
Custodian Bank | BNY Mellon Trust Company (Ireland) Limited |
Revision Company | EY |
Fiscal Year End | 30 June |
Swiss representative | State Street Bank International GmbH, München, Zweigniederlassung Zürich |
Swiss paying agent | State Street Bank International GmbH, München, Zweigniederlassung Zürich |
Germany | 30% tax rebate |
Switzerland | No ESTV Reporting |
Austria | Tax Reporting Fund |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | BNY Mellon Fund Services (Ireland) Limited |
Securities lending | No |
Securities lending counterparty |
Swedish Orphan Biovitrum AB | 5.03% |
Ionis Pharmaceuticals | 4.33% |
Vertex Pharmaceuticals, Inc. | 4.19% |
Chugai Pharmaceutical Co., Ltd. | 4.13% |
Pharma Mar SA | 3.74% |
Pharming Group | 3.41% |
AstraZeneca PLC ADR | 3.33% |
Sarepta Therapeutics | 3.31% |
Takeda Pharmaceutical Co., Ltd. | 3.29% |
BioMarin Pharmaceutical | 3.23% |
Health Care | 91.19% |
Other | 8.81% |
YTD | -4.98% |
1 month | -0.63% |
3 months | -4.98% |
6 months | -6.79% |
1 year | -13.58% |
3 years | -12.22% |
5 years | +1.95% |
Since inception (MAX) | +9.82% |
2023 | -15.14% |
2022 | +3.96% |
2021 | -2.71% |
2020 | +22.92% |
Volatility 1 year | 15.12% |
Volatility 3 years | 17.01% |
Volatility 5 years | 19.74% |
Return per risk 1 year | -0.90 |
Return per risk 3 years | -0.25 |
Return per risk 5 years | 0.02 |
Maximum drawdown 1 year | -20.61% |
Maximum drawdown 3 years | -25.17% |
Maximum drawdown 5 years | -25.17% |
Maximum drawdown since inception | -25.17% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | ETLI | - - | - - | - |
Borsa Italiana | EUR | BIOT | BIOT IM ETLIEUIV | BIOT.MI ETLIEURINAV=SOLA | Flow Traders B.V. |
Euronext Amsterdam | EUR | BIOT | BIOT NA ETLIEUIV | GOBIOT.AS ETLIEURINAV=SOLA | Flow Traders B.V. |
London Stock Exchange | GBX | BIGT | BIGT LN NA | BIGT.L NA | Flow Traders B.V. |
London Stock Exchange | USD | BIOT | BIOT LN NA | GEBIOT.L NA | Flow Traders B.V. |
SIX Swiss Exchange | CHF | BIOT | BIOT SW ETLIEUIV | BIOTC.S ETLIEURINAV=SOLA | Flow Traders B.V. |
XETRA | EUR | ETLI | ETLI GY ETLIEUIV | ETLI.DE ETLIEURINAV=SOLA | Flow Traders B.V. |
Fund name | Fund Size in m € (AuM) | TER in % p.a. | Distribution policy | Replication method |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 1,056 | 0.40% p.a. | Accumulating | Sampling |
L&G Healthcare Breakthrough UCITS ETF USD Acc | 70 | 0.49% p.a. | Accumulating | Full replication |
HANetf HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF | 16 | 0.59% p.a. | Accumulating | Full replication |
VanEck Genomics and Healthcare Innovators UCITS ETF A | 7 | 0.35% p.a. | Accumulating | Full replication |
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 3 | 0.30% p.a. | Accumulating | Full replication |